CXCR-4 expression on bone marrow CD34+ cells prior to mobilization can predict mobilization adequacy in patients with hematologic malignancies

Melissa Dabusti, Eros Ferrazzi, Gianluigi Castoldi, Francesco Lanza, Diana Campioni, Barbara Castagnari, Alessia Tieghi, Sabrina Moretti, Marina Punturieri, Cristiano De Angeli, Romedio Spanedda

Research output: Contribution to journalArticle

Abstract

To investigate the mechanisms of mobilization and of the factors implicated in the homing of progenitors and possibly understand the reasons for unpredicted mobilization failure, we analyzed CXCR-4 (CD184) expression on bone marrow (BM) CD34+ cells prior to peripheral blood stem cell (PBSC) mobilization in 24 patients affected by hematologic malignancies (non-Hodgkin lymphoma, multiple myeloma, and acute myeloid leukemia). We wanted to determine whether the level of CXCR-4 expressed by hematopoietic stem cells could influence mobilization process and therefore could be considered a predictive factor for mobilization adequacy. These data were also compared with stromal cell function as assessed by colony forming unit-fibroblast (CFU-F) and CFU endothelial cells (CFU-En) assays and stromal layer confluence capacity exhibited by patients' BM cells. In this study, we also compared CXCR-4 expression on CD34+ cells from different sources and at different migration stages specifically bone marrow (BM), steady state peripheral blood (SSPB), fetal cord blood (FCB), cord blood (CB), and mobilized PBSC. Seven (29%) of the 24 patients undergoing mobilization failed to achieve an adequate number of CD34+ stem cells (5 × 106/kg CD34 + cells) and showed a very high expression frequency of CXCR-4 on BM CD34+ stem cells (mean number of positive cells, 97%) investigated before the mobilization regimen. We also found that high expression intensity per cell for CXCR-4 was associated with lower amounts of mobilized CD34 + cells whereas those patients (17 out of 24 patients, 71%) with lower expression intensity per cell of CD184 on BM CD34+ cells prior to mobilization harvested at least 5 × 106/kg CD34+ cells. Setting a cut off of 5 × 106/kg CD34+ cells harvested, patients mobilizing less had a mean value of 97% CD34+ cells expressing CXCR-4 with a relative mean channel fluorescence of 458 whereas patients mobilizing more than 5 × 106/kg CD34 + progenitors showed a mean value of 59.8% CD34 +/CXCR-4+ cells with a relative mean channel fluorescence value of 305. Interestingly, in the poor mobilizers group, the marrow stromal microenvironment was found to be more severely damaged in comparison with that of good mobilizers. The comparative analysis of CXCR-4 expression showed no difference in percentage values between steady-state PB (87.4%) and BM (85.1%) stem cells whereas mobilized CD34+ stem cells have a lower expression frequency of CXCR-4 (71.6%) compared to that of progenitors from other sources. Fetal blood CD34+ stem cells had the lowest mean expression frequency of CD184 antigen (36.3%), while CB cells had the highest (94.8%). In conclusion, this study provides evidence that monitoring CXCR-4 CD34 double positive cells before mobilization can be regarded as a predictive factor for mobilization outcome, giving us directional cues for the choice of the best stem cell mobilization regimens.

Original languageEnglish
Pages (from-to)425-434
Number of pages10
JournalJournal of Hematotherapy and Stem Cell Research
Volume12
Issue number4
DOIs
Publication statusPublished - Aug 2003

Fingerprint

Hematologic Neoplasms
Bone Marrow Cells
Fetal Blood
Stem Cells
Bone Marrow
Hematopoietic Stem Cell Mobilization
Fluorescence
Stromal Cells
Hematopoietic Stem Cells
Multiple Myeloma
Acute Myeloid Leukemia
Non-Hodgkin's Lymphoma
Cues
Blood Cells
Endothelial Cells
Fibroblasts
Cell Count
Antigens

ASJC Scopus subject areas

  • Hematology
  • Immunology

Cite this

CXCR-4 expression on bone marrow CD34+ cells prior to mobilization can predict mobilization adequacy in patients with hematologic malignancies. / Dabusti, Melissa; Ferrazzi, Eros; Castoldi, Gianluigi; Lanza, Francesco; Campioni, Diana; Castagnari, Barbara; Tieghi, Alessia; Moretti, Sabrina; Punturieri, Marina; De Angeli, Cristiano; Spanedda, Romedio.

In: Journal of Hematotherapy and Stem Cell Research, Vol. 12, No. 4, 08.2003, p. 425-434.

Research output: Contribution to journalArticle

Dabusti, M, Ferrazzi, E, Castoldi, G, Lanza, F, Campioni, D, Castagnari, B, Tieghi, A, Moretti, S, Punturieri, M, De Angeli, C & Spanedda, R 2003, 'CXCR-4 expression on bone marrow CD34+ cells prior to mobilization can predict mobilization adequacy in patients with hematologic malignancies', Journal of Hematotherapy and Stem Cell Research, vol. 12, no. 4, pp. 425-434. https://doi.org/10.1089/152581603322286051
Dabusti, Melissa ; Ferrazzi, Eros ; Castoldi, Gianluigi ; Lanza, Francesco ; Campioni, Diana ; Castagnari, Barbara ; Tieghi, Alessia ; Moretti, Sabrina ; Punturieri, Marina ; De Angeli, Cristiano ; Spanedda, Romedio. / CXCR-4 expression on bone marrow CD34+ cells prior to mobilization can predict mobilization adequacy in patients with hematologic malignancies. In: Journal of Hematotherapy and Stem Cell Research. 2003 ; Vol. 12, No. 4. pp. 425-434.
@article{372a881e5e9f43fc87b1ffda03a768fc,
title = "CXCR-4 expression on bone marrow CD34+ cells prior to mobilization can predict mobilization adequacy in patients with hematologic malignancies",
abstract = "To investigate the mechanisms of mobilization and of the factors implicated in the homing of progenitors and possibly understand the reasons for unpredicted mobilization failure, we analyzed CXCR-4 (CD184) expression on bone marrow (BM) CD34+ cells prior to peripheral blood stem cell (PBSC) mobilization in 24 patients affected by hematologic malignancies (non-Hodgkin lymphoma, multiple myeloma, and acute myeloid leukemia). We wanted to determine whether the level of CXCR-4 expressed by hematopoietic stem cells could influence mobilization process and therefore could be considered a predictive factor for mobilization adequacy. These data were also compared with stromal cell function as assessed by colony forming unit-fibroblast (CFU-F) and CFU endothelial cells (CFU-En) assays and stromal layer confluence capacity exhibited by patients' BM cells. In this study, we also compared CXCR-4 expression on CD34+ cells from different sources and at different migration stages specifically bone marrow (BM), steady state peripheral blood (SSPB), fetal cord blood (FCB), cord blood (CB), and mobilized PBSC. Seven (29{\%}) of the 24 patients undergoing mobilization failed to achieve an adequate number of CD34+ stem cells (5 × 106/kg CD34 + cells) and showed a very high expression frequency of CXCR-4 on BM CD34+ stem cells (mean number of positive cells, 97{\%}) investigated before the mobilization regimen. We also found that high expression intensity per cell for CXCR-4 was associated with lower amounts of mobilized CD34 + cells whereas those patients (17 out of 24 patients, 71{\%}) with lower expression intensity per cell of CD184 on BM CD34+ cells prior to mobilization harvested at least 5 × 106/kg CD34+ cells. Setting a cut off of 5 × 106/kg CD34+ cells harvested, patients mobilizing less had a mean value of 97{\%} CD34+ cells expressing CXCR-4 with a relative mean channel fluorescence of 458 whereas patients mobilizing more than 5 × 106/kg CD34 + progenitors showed a mean value of 59.8{\%} CD34 +/CXCR-4+ cells with a relative mean channel fluorescence value of 305. Interestingly, in the poor mobilizers group, the marrow stromal microenvironment was found to be more severely damaged in comparison with that of good mobilizers. The comparative analysis of CXCR-4 expression showed no difference in percentage values between steady-state PB (87.4{\%}) and BM (85.1{\%}) stem cells whereas mobilized CD34+ stem cells have a lower expression frequency of CXCR-4 (71.6{\%}) compared to that of progenitors from other sources. Fetal blood CD34+ stem cells had the lowest mean expression frequency of CD184 antigen (36.3{\%}), while CB cells had the highest (94.8{\%}). In conclusion, this study provides evidence that monitoring CXCR-4 CD34 double positive cells before mobilization can be regarded as a predictive factor for mobilization outcome, giving us directional cues for the choice of the best stem cell mobilization regimens.",
author = "Melissa Dabusti and Eros Ferrazzi and Gianluigi Castoldi and Francesco Lanza and Diana Campioni and Barbara Castagnari and Alessia Tieghi and Sabrina Moretti and Marina Punturieri and {De Angeli}, Cristiano and Romedio Spanedda",
year = "2003",
month = "8",
doi = "10.1089/152581603322286051",
language = "English",
volume = "12",
pages = "425--434",
journal = "Journal of Hematotherapy and Stem Cell Research",
issn = "1525-8165",
publisher = "Mary Ann Liebert Inc.",
number = "4",

}

TY - JOUR

T1 - CXCR-4 expression on bone marrow CD34+ cells prior to mobilization can predict mobilization adequacy in patients with hematologic malignancies

AU - Dabusti, Melissa

AU - Ferrazzi, Eros

AU - Castoldi, Gianluigi

AU - Lanza, Francesco

AU - Campioni, Diana

AU - Castagnari, Barbara

AU - Tieghi, Alessia

AU - Moretti, Sabrina

AU - Punturieri, Marina

AU - De Angeli, Cristiano

AU - Spanedda, Romedio

PY - 2003/8

Y1 - 2003/8

N2 - To investigate the mechanisms of mobilization and of the factors implicated in the homing of progenitors and possibly understand the reasons for unpredicted mobilization failure, we analyzed CXCR-4 (CD184) expression on bone marrow (BM) CD34+ cells prior to peripheral blood stem cell (PBSC) mobilization in 24 patients affected by hematologic malignancies (non-Hodgkin lymphoma, multiple myeloma, and acute myeloid leukemia). We wanted to determine whether the level of CXCR-4 expressed by hematopoietic stem cells could influence mobilization process and therefore could be considered a predictive factor for mobilization adequacy. These data were also compared with stromal cell function as assessed by colony forming unit-fibroblast (CFU-F) and CFU endothelial cells (CFU-En) assays and stromal layer confluence capacity exhibited by patients' BM cells. In this study, we also compared CXCR-4 expression on CD34+ cells from different sources and at different migration stages specifically bone marrow (BM), steady state peripheral blood (SSPB), fetal cord blood (FCB), cord blood (CB), and mobilized PBSC. Seven (29%) of the 24 patients undergoing mobilization failed to achieve an adequate number of CD34+ stem cells (5 × 106/kg CD34 + cells) and showed a very high expression frequency of CXCR-4 on BM CD34+ stem cells (mean number of positive cells, 97%) investigated before the mobilization regimen. We also found that high expression intensity per cell for CXCR-4 was associated with lower amounts of mobilized CD34 + cells whereas those patients (17 out of 24 patients, 71%) with lower expression intensity per cell of CD184 on BM CD34+ cells prior to mobilization harvested at least 5 × 106/kg CD34+ cells. Setting a cut off of 5 × 106/kg CD34+ cells harvested, patients mobilizing less had a mean value of 97% CD34+ cells expressing CXCR-4 with a relative mean channel fluorescence of 458 whereas patients mobilizing more than 5 × 106/kg CD34 + progenitors showed a mean value of 59.8% CD34 +/CXCR-4+ cells with a relative mean channel fluorescence value of 305. Interestingly, in the poor mobilizers group, the marrow stromal microenvironment was found to be more severely damaged in comparison with that of good mobilizers. The comparative analysis of CXCR-4 expression showed no difference in percentage values between steady-state PB (87.4%) and BM (85.1%) stem cells whereas mobilized CD34+ stem cells have a lower expression frequency of CXCR-4 (71.6%) compared to that of progenitors from other sources. Fetal blood CD34+ stem cells had the lowest mean expression frequency of CD184 antigen (36.3%), while CB cells had the highest (94.8%). In conclusion, this study provides evidence that monitoring CXCR-4 CD34 double positive cells before mobilization can be regarded as a predictive factor for mobilization outcome, giving us directional cues for the choice of the best stem cell mobilization regimens.

AB - To investigate the mechanisms of mobilization and of the factors implicated in the homing of progenitors and possibly understand the reasons for unpredicted mobilization failure, we analyzed CXCR-4 (CD184) expression on bone marrow (BM) CD34+ cells prior to peripheral blood stem cell (PBSC) mobilization in 24 patients affected by hematologic malignancies (non-Hodgkin lymphoma, multiple myeloma, and acute myeloid leukemia). We wanted to determine whether the level of CXCR-4 expressed by hematopoietic stem cells could influence mobilization process and therefore could be considered a predictive factor for mobilization adequacy. These data were also compared with stromal cell function as assessed by colony forming unit-fibroblast (CFU-F) and CFU endothelial cells (CFU-En) assays and stromal layer confluence capacity exhibited by patients' BM cells. In this study, we also compared CXCR-4 expression on CD34+ cells from different sources and at different migration stages specifically bone marrow (BM), steady state peripheral blood (SSPB), fetal cord blood (FCB), cord blood (CB), and mobilized PBSC. Seven (29%) of the 24 patients undergoing mobilization failed to achieve an adequate number of CD34+ stem cells (5 × 106/kg CD34 + cells) and showed a very high expression frequency of CXCR-4 on BM CD34+ stem cells (mean number of positive cells, 97%) investigated before the mobilization regimen. We also found that high expression intensity per cell for CXCR-4 was associated with lower amounts of mobilized CD34 + cells whereas those patients (17 out of 24 patients, 71%) with lower expression intensity per cell of CD184 on BM CD34+ cells prior to mobilization harvested at least 5 × 106/kg CD34+ cells. Setting a cut off of 5 × 106/kg CD34+ cells harvested, patients mobilizing less had a mean value of 97% CD34+ cells expressing CXCR-4 with a relative mean channel fluorescence of 458 whereas patients mobilizing more than 5 × 106/kg CD34 + progenitors showed a mean value of 59.8% CD34 +/CXCR-4+ cells with a relative mean channel fluorescence value of 305. Interestingly, in the poor mobilizers group, the marrow stromal microenvironment was found to be more severely damaged in comparison with that of good mobilizers. The comparative analysis of CXCR-4 expression showed no difference in percentage values between steady-state PB (87.4%) and BM (85.1%) stem cells whereas mobilized CD34+ stem cells have a lower expression frequency of CXCR-4 (71.6%) compared to that of progenitors from other sources. Fetal blood CD34+ stem cells had the lowest mean expression frequency of CD184 antigen (36.3%), while CB cells had the highest (94.8%). In conclusion, this study provides evidence that monitoring CXCR-4 CD34 double positive cells before mobilization can be regarded as a predictive factor for mobilization outcome, giving us directional cues for the choice of the best stem cell mobilization regimens.

UR - http://www.scopus.com/inward/record.url?scp=12444280009&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12444280009&partnerID=8YFLogxK

U2 - 10.1089/152581603322286051

DO - 10.1089/152581603322286051

M3 - Article

C2 - 12965079

AN - SCOPUS:12444280009

VL - 12

SP - 425

EP - 434

JO - Journal of Hematotherapy and Stem Cell Research

JF - Journal of Hematotherapy and Stem Cell Research

SN - 1525-8165

IS - 4

ER -